Company Overview -卓越新能 is the first domestic company specializing in the research and production of biodiesel from waste oils, and it is a leading enterprise in ester-based biodiesel production in China [2][3] - The company has maintained profitability despite extreme tariff policies, showcasing superior cost control, supplier management, and sales channel expansion capabilities [2][3] - The company currently has ester-based production capacity of nearly 500,000 tons, with plans to expand biodiesel production to approximately 1.3 million tons [2][3] Industry Outlook - The biodiesel industry has significant growth potential, driven by domestic and international policy support, with the EU being the largest consumer of biodiesel globally [3] - The demand for biodiesel is expected to increase as carbon pricing and marginal cost improvements create profitability opportunities [3] - The company can mitigate the impact of EU anti-dumping duties by exporting to high-demand regions outside the EU and establishing production facilities in non-tax regions [3] Financial Projections - The company is projected to achieve revenues of 4.807 billion, 7.304 billion, and 8.529 billion yuan from 2025 to 2027, with year-on-year growth rates of 34.9%, 51.9%, and 16.8% respectively [4] - Net profits for the same period are expected to be 360 million, 619 million, and 774 million yuan, with growth rates of 141.6%, 71.8%, and 25.2% respectively [4] - The estimated EPS for 2025, 2026, and 2027 are 3.00, 5.15, and 6.45 yuan per share, with corresponding PE ratios of 15.37, 8.95, and 7.15 [4] Catalysts for Stock Price - New production capacity coming online both domestically and internationally [5] - Decrease in raw material costs [5] - Acceleration of demand growth driven by domestic policies [5]

Core Viewpoint - The A-share market has seen significant gains, with the Shanghai Composite Index reaching a nearly four-year high, and brokerage firms are increasing their dividend payouts, indicating a positive trend in shareholder returns [1][4][5]. Group 1: Dividend Trends - Many brokerage firms are doubling their dividend payouts for 2024 compared to 2023, with Huayin Securities' dividend scale reaching ten times that of 2023 [1][5]. - As of August 13, over ten companies have proposed mid-term dividend plans for 2025, a significant increase from only two and one in 2022 and 2023, respectively [1][8]. - The number of brokerages planning mid-term dividends has surged to 26 in 2024, with expectations for further increases in 2025 [1][8]. Group 2: Specific Brokerage Dividend Data - In terms of per-hand dividend payouts for 2024, GF Securities leads with 40 yuan, followed by China Merchants Securities and Huatai Securities at 37.7 yuan and 37 yuan, respectively [2][11]. - Huayin Securities has seen its total dividend scale for 2024 reach 1.08 billion yuan, a significant increase from 0.108 billion yuan in 2023 [5][6]. - Southwest Securities' 2024 dividend scale is over double that of 2023, reaching 5.65 billion yuan, with plans for three dividend distributions throughout the year [6][8]. Group 3: Dividend Payment Rates - Among brokerages with a payout ratio above 50%, Guolian Minsheng leads at 80.04%, followed by Hongta Securities and Southwest Securities at 63.59% and 61.76%, respectively [12][14]. - In contrast, major brokerages like China Merchants Securities and GF Securities maintain payout ratios around 30%, with some even below 20% [12][14]. Group 4: Future Dividend Planning - More than ten brokerages have established three-year shareholder return plans for 2024-2026, indicating a strategic focus on long-term shareholder value [9][10]. - The upcoming half-year reports, typically released in late August, are expected to coincide with the announcement of mid-term dividend plans, potentially increasing the number of brokerages disclosing such plans [9][10].

信达证券8月13日发布安杰思（688581.SH）研报称：1）本地化建设加强助力海外业务发展，新产品放 量缓解国内集采压力；2）投入加码赋能长期发展，利润增速有望加快。风险提示：新产品注册不及预 期；海外市场拓展不及预期；国内集采降价超预期。 （文章来源：每日经济新闻） ...

Group 1 - The company has announced the second phase of its restricted stock incentive plan, which aims to drive continuous growth in revenue and profit [2] - The company's self-owned brand is showing strong growth trends in sales [2] - The data empowerment system and research capabilities are creating product advantages for the company [2] Group 2 - The overseas production capacity expansion is progressing smoothly, with limited short-term impact expected on the OEM business [2]

Group 1 - The core viewpoint of the report is that Sanxin Medical (300453.SZ) is experiencing accelerated revenue growth, driven by rapid development in overseas markets [2] - The company's main business in blood purification continues to grow significantly, supported by a rich pipeline of products, indicating strong growth momentum [2] Group 2 - The report highlights that the company's income growth is speeding up quarter by quarter, indicating a positive trend in financial performance [2] - The overseas business expansion is a key driver of the company's growth, suggesting a successful strategy in international markets [2]

Core Viewpoint - The rise in illegal securities activities is correlated with the warming of capital market conditions, leading to significant financial losses for investors due to fraudulent schemes [1][2]. Summary by Sections Illegal Securities Activities - Multiple securities firms, including CITIC Securities, Galaxy Securities, and others, have reported cases of fraud where criminals impersonate legitimate companies and their staff to conduct illegal securities activities [1][2]. - The fraudulent schemes involve a comprehensive imitation system, including fake trading software and social media accounts, which mislead investors [2]. Fraud Techniques - Criminals have developed five main fraudulent tactics targeting investors' psychological weaknesses, such as the desire for high returns and trust in authority [4][5][6]. - Techniques include creating false trading channels, promising high returns, charging various fees, forging regulatory documents, and extending scams into offline activities [4][5][6]. Identification and Prevention - Securities firms have issued guidelines to help investors identify illegal activities, emphasizing the importance of verifying the legitimacy of institutions and their personnel [7][8]. - Key identification methods include checking the qualifications of the entity, scrutinizing website and software details, being cautious of exaggerated marketing claims, and ensuring that payments are made to legitimate company accounts [7][8].

Core Viewpoint - The rise in illegal securities activities is correlated with the warming of the capital market, leading to significant financial losses for investors due to fraudulent practices by criminals impersonating legitimate securities firms and their employees [1][2]. Summary by Sections Overview of Illegal Activities - Multiple securities firms, including CITIC Securities and Galaxy Securities, have reported cases of fraud where criminals impersonate their companies or employees, resulting in financial losses for investors [1]. - The fraudulent methods include a comprehensive imitation system that ranges from official branding to business scenarios, making it difficult for investors to discern the authenticity [2]. Methods of Fraud - Criminals have developed a series of counterfeit trading apps, with examples such as "GFZY" and "Institutional Terminal" from Guangfa Securities, which are designed to mislead investors [2]. - Social media platforms have become key venues for these scams, with fake groups and accounts established to lure investors into fraudulent schemes [2]. Impersonation of Employees - Fraudsters have been known to use the photos and personal information of both current and former employees to directly contact investors, creating a false sense of legitimacy [3]. Common Fraud Schemes - Five primary fraudulent schemes have been identified: 1. Creation of fake trading channels promising special access to entice investors to download illegal software [4]. 2. Promises of high returns and profit-sharing to lure investors into depositing funds [4]. 3. Collection of various fees under different pretexts, often leading to obstacles during withdrawal attempts [6]. 4. Forgery of regulatory documents to enhance the credibility of the scams [6]. 5. Offline activities that extend the deception beyond online platforms, increasing the likelihood of investor engagement [6]. Identification and Prevention - Securities firms have proposed four methods for investors to identify illegal activities: 1. Verify the qualifications of the entity involved in securities trading through official regulatory websites [7]. 2. Pay attention to discrepancies in URLs and software details to spot counterfeit platforms [8]. 3. Be cautious of exaggerated marketing claims and promises of guaranteed returns [8]. 4. Ensure that all transactions are conducted through official company accounts, avoiding personal accounts [8]. - Investors are advised to keep records of all communications and transactions related to fraudulent activities for potential legal action [8].

Group 1 - The core viewpoint of the article highlights that Xinda Securities' research indicates that Action Education's "100 School Plan" expansion is progressing smoothly, with a potential turnaround in fundamentals [1] - The company plans to open 100 branches in key cities across the country over the next 3 to 5 years, leveraging AI to enhance the selection, training, and support processes for branch managers [1] - From March to July 2025, the company successfully replicated 9 branch managers and formed a core team of 42 members, achieving a cumulative performance of 5.28 million yuan, with the fastest individual achieving sales of 1.62 million yuan within 70 days [1] Group 2 - Despite facing pressure on revenue and cash collections in the first half of 2025 due to a high base in the first half of 2024 and trade frictions, the company expects a positive outlook for the second half of 2025 [1] - The "100 School Plan" is expected to enhance efficiency and effectiveness through AI empowerment [1] - The profit forecast for the parent company is maintained at 301 million yuan, 350 million yuan, and 399 million yuan for the years 2025 to 2027, with the current stock price corresponding to a PE valuation of 15x, 13x, and 11x respectively, maintaining a "buy" rating [1]

Group 1 - The overall gross margin has started to improve on a quarter-on-quarter basis, with significant growth in the backend CDMO business [2] - Domestic demand is beginning to recover, and contributions from overseas major clients provide performance elasticity [2] - The company is comprehensively laying out high-growth emerging sectors such as targeted protein degradation drugs, peptides, oligonucleotide drugs, and ADC drugs [2]

Group 1 - Guosheng Jin控 reached the daily limit increase, indicating strong market interest [1] - Huijin Co., Hato Co., and Tianli Technology saw increases of over 5%, reflecting positive investor sentiment [1] - Other companies such as Xiangcai Co., GF Securities, Bank of China Securities, and Xinda Securities also experienced upward movement, suggesting a broader trend in the market [1]